---
title: "BridgeBio: Post Attruby Approval, Shares Don't Look Such Good Value - Rating Downgrade"
date: "2025-02-07 16:07:42"
summary: "cagkansayin/iStock via Getty Images  Investment Overview I last covered BridgeBio (NASDAQ:BBIO) in a note for Seeking Alpha back in mid-November - that was around two weeks before the Food and Drug Agency (\"FDA\") was expected to announce if the Palo Alto, California-based"
categories:
  - "seekalpha_articles"
lang:
  - "en"
translations:
  - "en"
tags:
  - "seekalpha_articles"
menu: ""
thumbnail: "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2039571588/image_2039571588.jpg"
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

![Yellow pause symbol on blue background.](https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2039571588/image_2039571588.jpg?io=getty-c-w750) 



cagkansayin/iStock via Getty Images





Investment Overview
-------------------

I last covered BridgeBio (NASDAQ:[BBIO](https://seekingalpha.com/symbol/BBIO "BridgeBio Pharma, Inc.")) in a [note for Seeking Alpha](https://seekingalpha.com/article/4737350-bridgebio-2-weeks-until-major-drug-approval-catalyst-a-buy-with-caveats) back in mid-November - that was around two weeks before the Food and Drug Agency ("FDA") was expected to announce if the Palo Alto, California-based

[seekalpha_articles](https://seekingalpha.com/article/4756024-bridgebio-post-attruby-approval-shares-dont-look-such-good-value)
